Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Satya Das"'
Autor:
Kristen K. Ciombor, Yoanna Pumpalova, Christina Wu, Tanios Bekaii-Saab, Mohamad Bassam Sonbol, Jordan Berlin, Gregory B. Lesinski, Zhengjia Chen, Bassel F. El-Rayes, Ibrahim Halil Sahin, Amber Draper, Subir Goyal, Sigurdis Haraldsdottir, Satya Das, Daniel H. Ahn
Publikováno v:
Oncologist
Background Immune checkpoint inhibitor (ICI) therapy is highly effective in metastatic mismatch repair-deficient (MMR-D) colorectal cancer (CRC). In this study, we evaluated molecular and clinical predictors of ICI response in MMR-D CRC. Materials an
Autor:
Satya Das, Taymeyah Al-Toubah, Ghassan El-Haddad, Eleonora Pelle, Mintallah Haider, Jonathan R. Strosberg
Publikováno v:
Endocr Relat Cancer
Peptide receptor radionuclide therapy (PRRT) using 177Lu-DOTATATE has been approved for the treatment of gastroenteropancreatic NETs. An understanding of benefits and risks is important for the appropriate implementation of this therapy. This review
Autor:
Arash Kardan, Thomas J. Giordano, Thorvardur R. Halfdanarson, Jennifer A. Chan, Lawrence S. Blaszkowsky, Christopher H. Lieu, Pamela Brock, Anthony P. Heaney, Boris W. Kuvshinoff, Satya Das, Whitney S. Goldner, Al B. Benson, Cindy Hochstetler, Beth Lynn, Heloisa P. Soares, Craig R. Sussman, Fouad Kandeel, Jin He, Daniel M. Halperin, Emily K. Bergsland, Jonathan R. Strosberg, Nataliya Uboha, Sajid A. Khan, Terence Z. Wong, Kimberly A. Miller, Michael C. Soulen, Martin J. Heslin, Venu G. Pillarisetty, Manisha H. Shah, Paxton V. Dickson, Nikolaos A. Trikalinos, Namrata Vijayvergia, Shagufta Shaheen, Diane Lauren Reidy, Sarimar N Agosto Salgado, Paul T. Fanta
Publikováno v:
Journal of the National Comprehensive Cancer Network : JNCCN. 19(7)
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Neuroendocrine and Adrenal Gland Tumors focus on the diagnosis, treatment, and management of patients with neuroendocrine tumors (NETs), adrenal tumors, pheochromocytomas, paraga
Autor:
Arvind Dasari, Satya Das
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology
Gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) represent the most common subtype of NETs. The incidence of all NETs, and specifically GEP NETs, has risen exponentially over the last three decades. Only within the past several years have th
Publikováno v:
Expert opinion on biological therapy. 21(12)
Introduction: Cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) represent inhibitory immune checkpoints. Combination immune checkpoint inhibitor (ICI) therapy with anti-CTLA-4 plus anti-PD-1 antibodies in preclinica
Autor:
Liping Du, David Eisner, Jordan Berlin, Marques L. Bradshaw, Martin P. Sandler, Shikha Jain, Aaron Jessop, Dominique Delbeke, Chirayu Shah, Dana Backlund Cardin, Laura W. Goff, Aimee Schad, Satya Das, Kristen K. Ciombor
Publikováno v:
Endocr Relat Cancer
We developed a clinical score (CS) at Vanderbilt Ingram Cancer Center (VICC) that we hoped would predict outcomes for patients with progressive well-differentiated neuroendocrine tumors (NETs) receiving therapy with Lutetium-177 (177Lu)-DOTATATE. Pat
Autor:
Arvind Dasari, Satya Das
Publikováno v:
Curr Oncol Rep
PURPOSE OF REVIEW: The purpose of our review is to explore global epidemiologic trends of gastroenteropancreatic (GEP) neuroendocrine tumors (NETs). Specifically, we sought to examine whether there are differences in incidence, prevalence, distributi
Autor:
Satya Das, Marc T. Roth
Publikováno v:
Expert Rev Anticancer Ther
INTRODUCTION: Microsatellite instability-high (MSI-H) colorectal cancer (CRC) represents a unique subset of CRC characterized by elevated neoantigen expression and a high degree of intraepithelial T-cell infiltrate. These characteristics make MSI-H t
Publikováno v:
Oncologist
Immune checkpoint inhibitors (ICIs) benefit rare subsets of gastrointestinal (GI) cancer patients. Significant interest exists to identify predictive biomarkers which may increase the applicability of ICI therapy for these patients. Programmed-death
Autor:
Satya Das, Dana Backlund Cardin
Publikováno v:
Curr Treat Options Oncol
Metastatic (and locally advanced) pancreatic adenocarcinoma (mPDA) represents a major challenge for the oncology community given the rising mortality burden from the disease and the preponderance of patients diagnosed with unresectable disease. Altho